Publication: Survivin - a universal tumor antigen
Authors
Andersen, M.H. ; thor Straten, P.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Tu m o r-associated antigens recognized by
cellular effectors of the immune system are potential
t a rgets for antigen-specific cancer immunotherapy.
These antigens are classified as tissue (melanocy t e ) -
s p e c i fic proteins, cancer-testis antigens (proteins
expressed in normal testis and various cancers), tumorspecific
peptides derived from mutations in tumor cells,
and others. Clinical studies with peptides and proteins
derived from these antigens have been initiated to study
the effi c a cy of inducing specific cytotoxic T
lymphocytes (CTL) responses in vivo. However, most of
the peptide epitopes used in these vaccination trials are
m e l a n o cy t e - s p e c i fic, and these peptides cannot be
applied for tumors of non-melanocyte origin.
Furthermore, the expression of most tumor antigens is
heterogeneous among tumors from different patients and
can even vary among metastases obtained from one
patient. Immune selection of antigen loss variants may
p r ove to be an additional obstacle for the clinical
applicability of most of the known CTL epitopes.
R e c e n t l y, a new tumor antigen, survivin, has been
identified on the basis of spontaneous CTL responses in d i fferent cancer patients. Survivin is expressed in most
human neoplasms, but not in normal, diff e r e n t i a t e d
tissues. Importantly, dow n r egulation or loss of surviv i n
would severely inflict the growth potential of the tumor
cell. Since survivin is expressed by a variety of different
tumors MHC-restricted survivin epitopes may serve as
important and widely applicable targets for anti-cancer
immunotherapeutic strategies.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.